Navigation Links
Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
Date:9/10/2008

PARSIPPANY, N.J., Sept. 10 /PRNewswire/ -- Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the appointment of Paul Korner, M.D., M.B.A. as Vice President, Medical Affairs. Dr. Korner will be responsible for Medical Affairs for Ferring's Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas as well as Product Safety.

"As a result of our continued and projected growth, we have expanded and realigned our management staff to best meet our business needs," said Wayne Anderson, President and CEO. "Dr. Korner is exceptionally well qualified to fill this new role, as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas."

Dr. Korner joins Ferring with a broad range of experience in medical affairs, clinical development, management and business development. Prior to joining Ferring, Dr. Korner was Vice President of Medical Affairs, Women's Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women's Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women's Health and Bone Repair for Wyeth Research.

Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of products includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R) (menotropins for injection, USP); REPRONEX(R) (menotropins for injection, USP); Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert for infertility. Ferring offers the Q-CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.

Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
2. GM Exec Joins Bio-Reaction Industries Board of Directors
3. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
4. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
5. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
6. James C. Powell Joins Nerites Board of Directors
7. Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons
8. Jan Gray Joins Resverlogix Board of Directors
9. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
10. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
11. Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):